Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

Finerenone is a novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonist with IC50 value of 18nM.

Esaxerenone is an aldosterone receptor antagonist. Esaxerenone may be potential useful for preventing or treating hypertension or disease caused by hypertension.

Eplerenone is both a selective aldosterone blocker and a CYP3A4 substrate.

Fludrocortisone Acetate

Potassium canrenoate, the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.